GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » Loans Receivable

ABL Bio (XKRX:298380) Loans Receivable : ₩0 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is ABL Bio Loans Receivable?

ABL Bio's Loans Receivable for the quarter that ended in Sep. 2024 was ₩0 Mil.


ABL Bio Loans Receivable Historical Data

The historical data trend for ABL Bio's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Bio Loans Receivable Chart

ABL Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial - - - - -

ABL Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ABL Bio Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


ABL Bio Loans Receivable Related Terms

Thank you for viewing the detailed overview of ABL Bio's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


ABL Bio Business Description

Traded in Other Exchanges
N/A
Address
2nd Floor, 16 Daewangpangyo-Ro 712, Beon-Gil, Bundang-Gu, Gyeonggi-do, Seongnam-si, KOR, 13488
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

ABL Bio Headlines

No Headlines